Macugen

(Pegaptanib)

Phase 3Small molecule

BBausch Health Americas, Inc.

Macugen is one of 68 small molecule programs targeting Cystoid Macular Edema. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

Cystoid Macular EdemaActive, not recruiting

Wet Age-Related Macular DegenerationActive, not recruiting

Age-Related Macular DegenerationActive, not recruiting

Cystoid Macular EdemaPreclinical

Active, not recruiting

Age-Related Macular DegenerationPhase 3

Active, not recruiting

Competition

Competitive Landscape

237 competitors in Age-Related Macular Degeneration

#DrugCompanyPhaseTrials

Lucentis

Roche

Phase 3

64 2

Eylea

Regeneron

Phase 3

44 3

Vabysmo

Roche

Phase 3

13 4

Beovu

Novartis

Phase 3

10 5

Macugen

Pfizer

Phase 3

6 6

Avastin

BBio-Thera Solutions

Phase 3

18 7

Retaane

AAlcon Research

Phase 3

5 8

Kenalog

BBausch Health Americas, Inc.

Phase 3

2 9

Forzinity

SStealth BioTherapeutics Inc.

Phase 3

2 10

Luye Pharma Conbercept

CChengdu Kanghong Biotech Co., Ltd.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Cystoid Macular Edema1 trial

Pegaptanib Therapy in Non-Infectious Uveitic Cystoid Macular Edema

Completed·WWake Forest University·N/A·NCT00790803·5 enrolled

Safety and Efficacy1 trial

A Safety and Efficacy Study Comparing the Combination Treatments of Verteporfin Therapy Plus One of Two Different Doses of Intravitreal Triamcinolone Acetonide and the Verteporfin Therapy Plus Intravitreal Pegaptanib

Completed· Novartis logo

Novartis·Phase 3·NCT00242580·111 enrolled

Age-Related Macular Degeneration1 trial

Subretinal Macugen® for Neovascular Age-Related Macular Degeneration

Unknown status·KKlinikum Ludwigshafen·Phase 3·NCT00788177·10 enrolled

Wet Age-Related Macular Degeneration1 trial

Observational Study Of The Long-Term Effect Of Macugen In Patients With Wet Age-Related Macular Degeneration

Completed· Pfizer logo

Pfizer··NCT01245387·1,001 enrolled

Unspecified1 trial

MAAM Study: Avastin and Macugen Versus Avastin Versus Macugen

Completed·TThe Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery·Phase 2·NCT00531336·60 enrolled

Regulatory

FDA Approval Timeline[4]

Dec 17, 2004

MACUGEN

NDA NDA021756

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Pegaptanib. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Pegaptanib compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Pegaptanib. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA021756). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Bausch Health Americas, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: BBausch Health Americas, Inc.

Macugen

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Cystoid Macular Edema1 trial

Safety and Efficacy1 trial

Age-Related Macular Degeneration1 trial

Wet Age-Related Macular Degeneration1 trial

Unspecified1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News